Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across GLOBUS MEDICAL's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
6 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
NuVasive, Inc. is a San Diego-based global medical technology company focused on spine surgery, known for its lateral access procedures and the Pulse enabling-technology platform spanning surgical planning, navigation, imaging and intraoperative neuromonitoring. Stock-for-stock merger at a fixed exchange ratio of 0.75 Globus Medical share per NuVasive share; pro forma ownership ~72% Globus Medical / ~28% NuVasive shareholders.
Our combination with NuVasive is a defining moment in our company's history. I'm incredibly proud of the strong legacy we've built at Globus Medical, and I look forward to delivering on the many opportunities for our surgeon customers and their patients as a combined company.David Paul — Executive Chairman, Globus Medical
The combination with Globus Medical is highly transformative-bringing together two leading companies with a shared vision to change the lives of more patients around the globe. I look forward to helping the combined organization transform the future of surgery.Chris Barry — former Chief Executive Officer, NuVasive
Dan Scavilla, President and CEO, Globus Medical (Sept 1, 2023 completion release): "We're thrilled to begin our journey together to create a leading global musculoskeletal company. With a relentless focus on changing patient lives, we're combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally."
Nevro Corp. is a Redwood City, California global medical device company delivering comprehensive solutions for the treatment of chronic pain, known for its high-frequency (HFX) spinal cord stimulation technology. approximately $250 million total equity value ($5.85 per share in cash).
This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions.Dan Scavilla — President and CEO, Globus Medical
We are thrilled to join Globus Medical as this will allow us to reach more patients globally with clinically proven, innovative products that significantly reduce the burden of chronic pain.Kevin Thornal — CEO and President, Nevro Corp.
Dan Scavilla, President and CEO, Globus Medical (April 3, 2025 completion release): "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much needed treatment option to patients suffering from chronic pain."
The international operations and distribution channels of Alphatec Holdings, Inc. (Nasdaq: ATEC), covering direct and distributor sales channels across Asia, Europe and the Americas, including subsidiaries in the UK, Italy, the Netherlands, France, Germany, Hong Kong, Japan, Brazil, China, Singapore and Australia. approximately $80 million in cash (plus a 5-year senior secured credit facility of up to $30 million extended to Alphatec).
Strategically, this acquisition gives us immediate access to Japan and increased presence and penetration in other key geographies, and significant scale, roughly doubling our international sales. In addition, we will be acquiring a talent pool of international sales professionals as well as an extensive network of international distributors.David Paul — Chairman and CEO, Globus Medical
Branch Medical Group, Inc. (BMG) is an Audubon, Pennsylvania manufacturer of high-precision medical devices that had been a third-party supplier to Globus Medical since 2005. approximately $57.0 million in cash plus $5.3 million deferred consideration (aggregate ~$52.9 million disclosed at signing, subject to working-capital adjustment).
On February 24, 2015, Globus Medical, Inc. entered into an Agreement and Plan of Merger with Branch Medical Group, Inc. ... The aggregate consideration for all of the outstanding equity interests of BMG is approximately $52.9 million in cash, subject to customary adjustment after closing for certain working capital items and indebtedness.Globus Medical — 8-K dated March 2, 2015 (Item 1.01)
StelKast, Inc. is a privately held company that designs, manufactures and distributes orthopedic implants for knee and hip replacement surgeries. approximately $28.4 million net assets (about $24.1 million cash at closing plus up to $4.3 million contingent consideration based on product-sales milestones).
The StelKast acquisition should serve as a platform to expand our products and services into the Total Joint Arthroplasty market. Globus Medical's proven product development engine and history of innovation, when combined with our computer assisted technologies in Imaging, Navigation and Robotics, have the potential to improve clinical care for joint arthroplasty patients and create value for shareholders.David Paul — Executive Chairman, Globus Medical
Nemaris, Inc. is a privately held company that markets and develops Surgimap, a surgical planning software platform; substantially all of the acquired value was in developed technology. approximately $15.2 million (asset purchase).
On September 5, 2018, we acquired Nemaris, Inc. ("Nemaris"), a privately held company that markets and develops Surgimap, a surgical planning software platform. ... the Nemaris Acquisition was accounted for as an asset purchase. We allocated the consideration paid of $15.2 million on a pro rata basis to the assets acquired.Globus Medical — Q2 2019 Form 10-Q, Business Combinations note